Using Medroxyprogesterone Acetate for Contraception After Abortion
Continuation Rates of Self-administered Subcutaneous Depot Medroxyprogesterone Acetate and Provider-administered Intramuscular Depot Medroxyprogesterone Acetate in Patients Seeking Post-abortion Contraception
PHASE4 · Northwestern University · NCT05505435
This study is testing whether women who have just had an abortion prefer giving themselves a birth control shot at home or getting it from a healthcare provider.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 653 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Northwestern University (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05505435 on ClinicalTrials.gov |
What this trial studies
This study investigates the continuation rates of self-administered Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) compared to provider-administered Intramuscular Depot Medroxyprogesterone Acetate (DMPA-IM) in post-abortion patients. Conducted at a large abortion clinic in Chicago, Illinois, the study will recruit patients who desire DMPA for contraception after their abortion. Participants will complete a baseline survey to gather demographic and clinical data and will choose between the two administration methods. The goal is to assess the effectiveness and acceptability of self-administered DMPA-SC in this specific population.
Who should consider this trial
Good fit: Ideal candidates are patients seeking contraception after an abortion who are planning to use DMPA.
Not a fit: Patients who cannot read or speak English may not benefit from this study due to communication barriers.
Why it matters
Potential benefit: If successful, this study could improve contraceptive continuation rates for patients post-abortion.
How similar studies have performed: Previous studies have shown higher continuation rates for self-administered DMPA-SC, but this specific focus on post-abortion patients is less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient planning DMPA for post-abortion contraception. Exclusion Criteria: * Patient cannot speak and read English.
Where this trial is running
Chicago, Illinois
- Family Planning Associates — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Study coordinator: Ashley Turner, MD
- Email: ashley.turner1@nm.org
- Phone: 312-926-8678
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Contraception